In the coming years there will probably be a Cardio-Oncology ‘epidemic’ due to either the growing population of cancer survivors, the increasing number of patients aged over 65 who need chronic cancer therapy and the high frequency of cancer therapy induced CVDs in these populations. The main goal of Cardio-Oncology is to reduce the burden of CVDs in oncologic patients allowing them to receive the best antitumor therapy (chemotherapy, targeted molecular therapies, hormone therapy, immunotherapy or radiotherapy) with the lowest rate of side effects and treatment interruptions.
Consequently, the ESC created the Council of Cardio-Oncology in August 2018 as a multidisciplinary constituent body which encourages the prevention, early diagnosis and management of cancer therapy-related cardiovascular diseases.
Vision:
Their aims are to bring together European & non-European specialists in the field and specialists from Oncology, Hematology, Radiotherapy and related disciplines to improve the prevention, diagnosis, treatment and management of cancer therapy-related cardiovascular diseases and enhance the standard of care for Cardio-Oncology patients.
They work in line with the ESC Strategic Pillars: Advocacy, Congresses, Research, Membership and Education.
Mission:
To reduce the burden of cardiovascular disease.